Summary: Treating insomnia when a patient also has Obstructive Sleep Apnea (OSA)—a condition known as COMISA—is a delicate balancing act. While sedative-hypnotics can help patients fall asleep, there has long been a fear that these drugs might “over-relax” the airway muscles, worsening apnea events and dropping oxygen levels.
A landmark systematic review and network meta-analysis analyzed 32 randomized controlled trials to determine which medications offer the best sleep architecture without compromising respiratory safety.
Key Facts
- The Respiratory Myth: The study found no broad evidence that most hypnotics uniformly worsen respiratory outcomes. Master metrics like the Apnea-Hypnea Index (AHI) remained stable compared to placebos for most drugs.
- The Temazepam Exception: Not all drugs were cleared. Temazepam, a benzodiazepine, was found to significantly decrease arterial oxygen saturation during sleep, suggesting it may be riskier for OSA patients.
- Tailored Treatment: The researchers emphasized that drug selection must be “symptom-specific.” Some patients struggle with falling asleep (sleep onset), while others struggle with waking up too early (sleep maintenance).
- CPAP Neutrality: The study accounted for both CPAP users and non-users, ensuring the results are applicable to patients who cannot tolerate breathing machines.
- First-of-its-Kind: This is the first network meta-analysis to comprehensively compare multiple hypnotics across both sleep quality and respiratory safety in adults with OSA.
Source: Fujita Health University
OSA is a common sleep disorder characterized by oxygen desaturation due to repeated airway collapse during sleep. This leads to oxygen desaturation or awakening from sleep. It is often linked to metabolic problems, cardiovascular disease, and a lower quality of life. OSA and insomnia symptoms often co-occur, a condition known as comorbid insomnia and sleep apnea or COMISA. This can complicate usual treatments like continuous positive airway pressure (CPAP) therapy, which is often recommended for moderate to severe OSA management.
Although Clinical Practice Guidelines generally recommend cognitive behavioral therapy for insomnia symptoms in individuals with OSA, medications are often preferred and prescribed in real-world settings. However, concerns remain that some of the common sedative-hypnotics could worsen respiratory parameters and lead to aggravated OSA symptoms.
Recently, researchers from Japan, led by Professor Taro Kishi from the Department of Psychiatry, Fujita Health University School of Medicine, Japan, conducted a systematic review and network meta-analysis to identify the hypnotics providing optimal sleep architecture without compromising the respiratory safety in adults with OSA. Professor Tsuyoshi Kitajima, Professor Nakao Iwata, and Dr. Kenji Sakuma, also from the Department of Psychiatry, Fujita Health University School of Medicine, were a part of the research group.
The study findings were made available online on February 10, 2026, in the academic journal of the Japanese Society of Psychiatry and Neurology, Psychiatry and Clinical Neurosciences.
“The hypnotics used for insomnia in patients with OSA have varied effects on sleep quality and respiratory function. Our research aims to enable safer and more effective drug selection that considers the respiratory risks and is tailored to each patient’s symptoms,” mentions Prof. Kishi while talking about the motivation underlying the study.
The researchers conducted a network meta-analysis of 32 randomized controlled trials for 12 types of hypnotic medications, including brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, zopiclone, and placebo.
17 distinct outcomes, categorized into sleep architecture, respiratory function, treatment acceptability, treatment tolerability, and other safety outcomes, were assessed for the study.
The hypnotics showed varied effectiveness in treating insomnia. Highlighting the importance of this finding, Prof. Kitajima mentions, “While some patients reported difficulty in falling asleep, others reported waking up in the middle of the night or early in the morning. Suggesting appropriate medication, based on the symptom of insomnia, can aid in alleviating the problem effectively.”
Additionally, “Since our network meta-analysis included both CPAP users and non-users, we have focused on the sensitivity analysis results while excluding CPAP users and titration studies,” Dr. Sakuma emphasized.
The biggest concern for OSA patients when using sleep-inducing medication is the worsening of apnea and hypopnea. Overall, the study did not find broad evidence that hypnotics uniformly worsened respiratory outcomes. Important metrics like apnea-hypopnea index did not significantly differ from placebo for most of the analyzed drugs.
Conversely, temazepam, a benzodiazepine hypnotic, was found to decrease arterial oxygen saturation during sleep. Considering the limitations of this study, clinicians are advised to individualize treatment, carefully weigh potential benefits and risks, and monitor respiratory status when prescribing hypnotics to patients with OSA.
“This is the first network meta-analysis to comprehensively compare multiple hypnotics across both sleep architecture and respiratory parameters in adults with OSA. This allows us to establish the requirement of tailoring medication based on specific symptoms associated with insomnia.
“Clinical trials that verify the effectiveness of each sleeping medication on patients’ specific insomnia symptoms can help in the formal synthesis of subjective outcomes in the future,” concludes Prof. Iwata.
Funding information
This work was supported by JSPS KAKENHI Grant Number 25K10874 (Grant-in-Aid for Scientific Research(C)).
Key Questions Answered:
A: According to this massive analysis of 12 different drugs, the answer for most modern hypnotics is “yes.” For a long time, doctors were afraid that sleeping pills would make your tongue and throat muscles so relaxed that your airway would collapse more often. However, this study shows that for most medications, those “respiratory parameters” didn’t actually get worse.
A: The study flagged Temazepam (a benzodiazepine) because it was linked to lower oxygen levels in the blood during sleep. While many other drugs were safe, this finding reinforces that you shouldn’t just grab any sleep aid off the shelf—it needs to be tailored to your specific type of insomnia and your respiratory health.
A: CPAP is the “gold standard” because it physically keeps your airway open. Sleeping pills only treat the symptom (insomnia), not the cause (the airway collapse). However, for people with COMISA who find it impossible to sleep with a mask on, these findings offer a “plan B” to help them get the rest they need without fear of stopping their breathing.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this OSA and neuropharmacology research news
Author: Hisatsugu Koshimizu
Source: Fujita Health University
Contact: Hisatsugu Koshimizu – Fujita Health University
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Comparative effects of hypnotic agents on sleep architecture and respiratory outcomes in obstructive sleep apnea: A systematic review and network meta-analysis” by Taro Kishi MD, PhD, Toshikazu Ikuta PhD, Kenji Sakuma MD, PhD, Masakazu Hatano PhD, Tatsuhiko Kishi MD, Tsuyoshi Kitajima MD, PhD, Nakao Iwata MD, PhD. Psychiatry and Clinical Neurosciences
DOI:10.1111/pcn.70036
Abstract
Comparative effects of hypnotic agents on sleep architecture and respiratory outcomes in obstructive sleep apnea: A systematic review and network meta-analysis
Aim
This network meta-analysis of randomized controlled trials (RCTs) aimed to investigate which hypnotics are associated with the most favorable sleep architecture and respiratory outcomes in adults with obstructive sleep apnea.
Methods
Primary outcomes included total sleep time (TST) and apnea–hypopnea index (AHI) during TST. Other outcomes were rapid eye movement (REM) sleep time, latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), AHI during non-REM or REM sleep, mean peripheral oxygen saturation (SpO2) during TST, mean SpO2 nadir during TST, arousal index (AI), all-cause discontinuation, adverse event-related discontinuation, and incidence of individual adverse events. Effect sizes with 95% confidence intervals were calculated.
Results
This systematic review included 32 RCTs (n = 1871, average age = 51.60 years, 62.52% male, mean AHI = 23.60). Our network meta-analysis evaluated brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, zopiclone, and placebo. Compared with placebo, lemborexant increased TST, REM sleep time, and SE and decreased LPS and WASO, whereas both daridorexant and zolpidem increased TST and SE and decreased WASO. These three medications demonstrated respiratory safety and discontinuation profiles similar to those of placebo. Eszopiclone increased TST and SE and decreased LPS, WASO, AHI during TST, and AI, but its effects on LPS, WASO, AHI during TST, and AI disappeared in the sensitivity analysis, excluding continuous positive airway pressure titration studies.
Conclusion
Our network meta-analysis identified different effects of various hypnotics on sleep architecture and respiratory parameters; however, the lack of data prevented a formal synthesis of subjective outcomes. Therefore, these results should be interpreted with caution in clinical practice.
